| 34.8 -35.395 (-50.42%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 78.96 |
1-year : | 103.95 |
| Resists | First : | 67.6 |
Second : | 89 |
| Pivot price | 79.63 |
|||
| Supports | First : | 32.99 |
Second : | 27.44 |
| MAs | MA(5) : | 70.21 |
MA(20) : | 80.75 |
| MA(100) : | 76.9 |
MA(250) : | 0 | |
| MACD | MACD : | -3.9 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 6.9 |
D(3) : | 20.9 |
| RSI | RSI(14): 14.8 |
|||
| 52-week | High : | 117.33 | Low : | 32.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CORT ] has closed below the lower bollinger band by 38.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CORT ] is to continue within current trading range. It is unclear right now based on current values. 312.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 39.06 - 39.33 | 39.33 - 39.54 |
| Low: | 32.37 - 32.69 | 32.69 - 32.94 |
| Close: | 34.34 - 34.79 | 34.79 - 35.14 |
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Wed, 31 Dec 2025
Why Corcept (CORT) Shares Are Falling Today - Yahoo Finance
Wed, 31 Dec 2025
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Wed, 31 Dec 2025
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Wed, 31 Dec 2025
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Wed, 31 Dec 2025
Why Is Corcept Therapeutics Stock Sinking Wednesday? - Corcept Therapeutics (NASDAQ:CORT) - Benzinga
Wed, 31 Dec 2025
Corcept sinks as FDA rejects hormonal disorder therapy - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 75.5 (%) |
| Shares Short | 10,340 (K) |
| Shares Short P.Month | 11,050 (K) |
| EPS | 0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.01 |
| Profit Margin | 14.3 % |
| Operating Margin | 4.9 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 16.7 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 6.91 |
| Sales Per Share | 7.04 |
| EBITDA (p.s.) | 0.63 |
| Qtrly Earnings Growth | -61 % |
| Operating Cash Flow | 163 (M) |
| Levered Free Cash Flow | 136 (M) |
| PE Ratio | 40 |
| PEG Ratio | 0 |
| Price to Book value | 5.79 |
| Price to Sales | 4.93 |
| Price to Cash Flow | 22.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|